Epstein-Barr virus infection

New England Journal of Medicine

Volumn 343, Issue 7, 2000, Pages 481-492

  Cohen, Jeffrey I ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CELL NUCLEUS ANTIGEN; CORTICOSTEROID; EPSTEIN BARR VIRUS ANTIGEN; LATENT MEMBRANE PROTEIN 1; VIRUS DNA; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTIOUS MONONUCLEOSIS; LEUKOPLAKIA; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIMARY INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS GENE; VIRUS REPLICATION;

EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; NEOPLASMS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0034680005     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200008173430707     Document Type: Review

References (102)

1. Virus particles in cultured lymphoblasts from Burkitt's lymphoma
2. Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis
3. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx
4. Outbreak of Burkitt's-like lymphoma in homosexual men
5. Replication of Epstein-Barr virus within the epithelial cells of oral 'hairy' leukoplakia, an AIDS-associated lesion
6. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections
7. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease
8. An animal model for acute and persistent Epstein-Barr virus infection
9. Epstein-Barr virus receptor of human B lymphocytes in the C3d receptor CR2
10. Epstein-Barr virus uses HLA class II as a cofactor for infection of B lymphocytes
11. X-linked agammaglobulinemia patients are not infected with Epstein-Barr virus: Implications for the biology of the virus
12. Epstein-Barr virus and its replication
13. Replication of Epstein-Barr virus in human epithelial cells infected in vitro
14. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals
15. Epstein-Barr virus replication in oropharyngeal epithelial cells
16. Role of epithelium in EBV persistence and pathogenesis of B-cell tumours
17. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: Implications for the interindividual infection route of Epstein-Barr virus
18. Epstein-Barr virus (EBV) infection in infectious mononucleosis: Virus latency, replication and phenotype of EBV-infected cells
19. Epstein-Barr virus and the immune system: Hide and seek
20. EBV persistence in memory B cells in vivo
21. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers
22. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: Implications for sites of viral latency
23. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders
24. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells
25. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1
26. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23
27. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
28. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice
29. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses
30. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family
31. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients
32. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases
33. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals
34. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata
35. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: Cell phenotype dependence of viral promoter usage
36. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state
37. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
38. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo
39. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers
40. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI
41. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1
42. Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells
43. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1
44. Epstein-Barr virus-coded BHRF1 protein, a viral homolog of Bcl-2, protects human B cells from programmed cell death
45. Vaccine strategies against Epstein-Barr virus-associated diseases: Lessons from studies on cytotoxic T-cell-mediated immune regulation
46. Infectious mononucleosis in Rochester, Minnesota, 1950 through 1969
47. NIH conference: Epstein-Barr virus infections: Biology, pathogenesis, and management
48. The chronic mononucleosis syndrome
49. Epstein-Barr virus infections in males with the X-linked lymphoproliferative syndrome
50. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM
51. Cutting edge: Human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP
52. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China
53. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma
54. Population screening for EBV markers: Toward improvement of nasopharyngeal carcinoma control
55. Enzyme-linked immunosorbent assay of antibodies to Epstein-Barr virus nuclear and early antigens in patients with infectious mononucleosis and nasopharyngeal carcinoma
56. Down-regulation of LFA-1 adhesion receptors by C-myc oncogene in human B lymphoblastoid cells
57. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study
58. The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: Two new developments in the EBV field
59. Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data
60. Hodgkin's disease and Epstein-Barr virus: Altered antibody patterns before diagnosis
61. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency
62. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders
63. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant patients
64. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
65. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease
66. Interleukin-6 production in posttransplant lymphoproliferative disease
67. Central-nervous-system lymphoma related to Epstein-Barr virus
68. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation
69. Gastric carcinoma: Monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein
70. Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1
71. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: Different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma
72. Natural history of Epstein-Barr virus infection in a prospective pediatric cohort born to human immunodeficiency virus-infected mothers
73. Oral hairy leukoplakia: Clinicopathologic features, pathogenesis, diagnosis, and clinical significance
74. Opportunistic lymphoproliferations associated with Epstein-Barr viral DNA in infants and children with AIDS
75. Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma
76. AIDS-related lymphoma: Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization
77. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus
78. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma
79. Diagnosis of AIDS-related focal brain lesions: A decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF
80. Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS
81. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis
82. Regression of oral hairy leukoplakia after orally administered acyclovir therapy
83. Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double-blind, placebo-controlled study
84. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
85. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants
86. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome
87. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation
88. Humanized anti-CD20 monoclonal antibody (rituximab) in B posttransplant lymphoproliferative disorders (B PTLDs): A retrospective analysis of 32 patients
89. Aggressive treatment for postcardiac transplant lymphoproliferation
90. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts
91. Immunotherapy for Epstein-Barr virus-associated cancers
92. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes
93. Autologous lymphokineactivated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients
94. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
95. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
96. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants: CAMPATH users
97. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy
98. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients
99. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children
100. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine
101. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen
102. Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for EBV subunit vaccine